Prostate Specific Antigen News and Research

RSS

Obese men may have elevated risk of biochemical recurrence after radical prostatectomy

Among men with prostate cancer who underwent radical prostatectomy (RP), those who were obese had a higher risk of biochemical recurrence, according to data presented at the American Association for Cancer Research Special Conference Obesity and Cancer: Mechanisms Underlying Etiology and Outcomes, held Jan. 27-30.

27 Jan 2018

Novel polygenic hazard score captures age variations of aggressive prostate cancer

An international team, led by researchers at the University of California San Diego School of Medicine, has developed and validated a genetic tool for predicting age of onset of aggressive prostate cancer, a disease that kills more than 26,000 American men annually.

12 Jan 2018

PET scans can predict prostate cancer patients’ response to salvage radiation treatment

For prostate cancer patients who have rising levels of PSA (a cancer indicator) even after radical prostatectomy, early treatment makes a difference.

5 Dec 2017

Use of Prostate Health Index cuts down need for uncomfortable biopsies

The Prostate Health Index is a cost-effective tool used by urologists to detect prostate cancer. It reduces the risk of over diagnosis, and cuts down on the need to send men for unnecessary and often uncomfortable biopsies.

20 Nov 2017

Common factors that could change your PSA test results

Most men in their 50s, who face an increasing risk of prostate cancer as they age, are familiar with the common screening exam known as the prostate specific antigen (PSA) test. But many are less familiar with how the test works and why different factors, such as prescription medications and infections, can influence the test results.

28 Oct 2017

What men need to know: Prevention, diagnosis, and treatment of prostate cancer

Prostate cancer is the second leading cause of cancer death in men. Next to skin cancers, prostate cancer is the most common cancer diagnosed in American men.

25 Oct 2017

UTSA professor awarded grant to support development of prostate cancer detection method

Jing Yong Ye, professor of biomedical engineering at The University of Texas at San Antonio (UTSA), has received a two-year, $354,617 grant from the National Institutes of Health's National Cancer Institute to support the development of his noninvasive method of detecting prostate cancer.

25 Sep 2017

Nanoparticle bling could increase sensitivity of test strips for better cancer detection

The most common test strip people might think of for diagnosis is a home pregnancy test. Pregnant women have steadily increasing levels of the biomarker human chorionic gonadotropin (hCG), which is easily detectable in urine and a thin, colorful strip of antibodies will appear when hCG is present.

13 Sep 2017

‘Nanoswitches’ could be key to faster, more sensitive tests for detection of biomarkers

Engineered strands of DNA -- nanoscale tools called "nanoswitches" -- could be the key to faster, easier, cheaper and more sensitive tests that can enable high-fidelity detection of biomarkers indicating the presence of different diseases, viral strains and even genetic variabilities as subtle as a single-gene mutation.

12 Sep 2017

Blood tumor markers could be useful in monitoring therapeutic outcomes for lung cancer patients

For many years, oncologists have known that cancers can secrete complex molecules into the blood and that levels of these molecules can be easily measured. These so-called 'tumor markers' are traditionally associated with a single dominant cancer type, for example Prostate Specific Antigen (PSA) linked to prostate cancer, Carcinoembryonic antigen (CEA) to colorectal cancer, CA125 to ovarian cancer, CA19.9 to pancreatic cancer and CA27.29 to breast cancer.

6 Sep 2017

Prostate cancer screening reduces cancer deaths finds new analysis

There has been much debate regarding the utility of prostate cancer screening in reducing the rates of deaths due to this cancer among men. While the ERSPC (European Randomized Study of Screening for Prostate Cancer) suggests that screening reduced prostate cancer deaths, the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found that regular screening does not reduce the cancer death rates in prostate cancer. Researchers thus looked at the actual picture as to which of these – ERSPC or PLCO are correct.

5 Sep 2017

Diagnosing prostate cancer through a £225 urine test

This test, which we have branded SelectMDx for Prostate Cancer, came with the acquisition of a company in the Netherlands called NovioGendix. They developed a prototype assay, so they did most of the heavy lifting in terms of discovering the two specific biomarkers that are currently in the product. These biomarkers are tuned towards the detection of what I call clinically significant prostate cancer.

24 Jul 2017

Surgery may not prolong life in men with early-stage prostate cancer

A major 20-year study provides further evidence that prostate cancer surgery offers negligible benefits to many men with early-stage disease.

13 Jul 2017

New biosensor technology could be used in wearable devices to monitor health

Imagine wearing a device that continuously analyzes your sweat or blood for different types of biomarkers, such as proteins that show you may have breast cancer or lung cancer.

13 Jun 2017

New diagnostic test uses machine learning to accurately detect aggressive prostate cancer

A new diagnostic developed by Alberta scientists will allow men to bypass painful biopsies to test for aggressive prostate cancer.

9 Jun 2017

New IsoPSA assay detects prostate cancer more precisely than current tests

A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures - distinguishing cancer from benign conditions, and identifying patients with high-risk disease.

15 May 2017

Study highlights need for personalized approaches to prostate cancer screening in high-risk black men

A new study indicates that higher prostate cancer death rates among black men in the US may be due to a higher risk of developing preclinical prostate cancer as well as a higher risk of that cancer progressing more quickly to advanced stages.

24 Apr 2017

U.S. Preventive Services Task Force supports Prostate Cancer Screening in men aged 55–69

The Men's Health Network (MHN) is positive on the most recent recommendations of the U.S. Preventive Services Task Force (USPSTF). The task force states that the choice of whether to be screened or not for prostate cancer depends on the men.

12 Apr 2017

Protein testing may become potential tool to detect prostate cancer

In 2016, more than 181,000 new cases of prostate cancer were reported in the U.S., according to the American Cancer Society. The prostate-specific antigen (PSA) test is one of the earliest ways clinicians can detect prostate cancers in their patients.

5 Apr 2017

Scientists find new way to detect prostate cancer by 'sniffing' urine

On the list of dreaded medical tests, a prostate biopsy probably ranks fairly high. The common procedure requires sticking a needle into the prostate gland to remove tissue for assessment.

4 Apr 2017